Mechanistic Insights into the Enhancement of Adeno-Associated Virus Transduction by Proteasome Inhibitors
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Proteasome inhibitors (e.g., bortezomib, MG132) are known to enhance adeno-associated virus (AAV) transduction; however, whether this results from pleotropic proteasome inhibition or off-target serine and/or cysteine protease inhibition remains unresolved. Here, we examined recombinant AAV (rAAV) effects of a new proteasome inhibitor, carfilzomib, which specifically inhibits chymotrypsin-like proteasome activity and no other proteases. We determined that proteasome inhibitors act on rAAV through proteasome inhibition and not serine or cysteine protease inhibition, likely through positive changes late in transduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another proteasome inhibitor, car fi lzomib, also enhanced AAV2 transduction in mice, however, to a lesser extent than bortezomib (68).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [68]
In the citing paper
“Both bortezomib and carfilzomib enhance rAAV2 transduction in vitro, but bortezomib is more efficacious than carfilzomib in vivo when administered by retro-orbital injection with rAAV2 (56).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [56]
Citations
Cites
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,614
Human and mouse proteases: a comparative genomic approach
Puente, X. S., Sánchez, L. M., Overall, C. M., & López-Otín, C. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1111 · Cited by 943 · cited 1×
“Unlike other classes of proteases, active site threonine of the proteasome is the N-terminal residue of each catalytic subunit, exposing the amino group to possible reactivity (31).”
BackgroundKuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationAntitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678 · cited 3×
“Carfilzomib, a second-generation PI, relies on this amino group to form a morpholino, covalently inhibiting cleavage (32), and so cannot inhibit other proteases (33, 34).”
BackgroundMethodProduction and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581 · cited 1×
“To address the question of whether a specific PI is sufficient to enhance rAAV transduction, we utilized three PIs, MG132, bortezomib, and carfilzomib (Selleck Chemicals), and an rAAV serotype 2 (rAAV2) vector expressing luciferase or enhanced green fluorescent protein (EGFP) transgenes (35).”
MethodSelf-citationGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Self-citationArastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408 · cited 1×
“neurotoxicity (30), demonstrating the importance of off-target”
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 3×
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
BackgroundResultTsubuki, S., Saito, Y., Tomioka, M., Ito, H., & Kawashima, S. (1996) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021280 · Cited by 306
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Douar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. (2000) · Worldwide Protein Data Bank · doi:10.2210/pdb1g65/pdb · Cited by 253 · cited 1×
“Carfilzomib, a second-generation PI, relies on this amino group to form a morpholino, covalently inhibiting cleavage (32), and so cannot inhibit other proteases (33, 34).”
BackgroundZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 1×
“tion (27, 28) appears to be necessary for ubiquitination, and the”
BackgroundYan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Russell, D. W., Alexander, I. E., & Miller, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5719 · Cited by 218
Sin, N., Kim, K. B., Elofsson, M., Meng, L., Auth, H., Kwok, B. H. B., & Crews, C. M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00376-5 · Cited by 207 · cited 1×
“Carfilzomib, a second-generation PI, relies on this amino group to form a morpholino, covalently inhibiting cleavage (32), and so cannot inhibit other proteases (33, 34).”
BackgroundEnhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus
Johnson, J. S., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.02309-08 · Cited by 162 · cited 2×
“We coadministered the drugs with 1,000 vector genomes per cell (vg/cell) rAAV2 to HeLa cells and compared their effects on transduction at 24 h (8).”
MethodResultSelf-citationZhong, L., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje-McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 146 · cited 2×
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
BackgroundResultYan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., & Engelhardt, J. F. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2863-2874.2004 · Cited by 138
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Self-citationPajusola, K., Gruchala, M., Joch, H., Lüscher, T. F., Ylä-Herttuala, S., & Büeler, H. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11530-11540.2002 · Cited by 111
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Self-citationAkache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 85
Enhancing transduction of the liver by adeno-associated viral vectors
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., & Davidoff, A. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.137 · Cited by 77 · cited 1×
“bortezomib (11, 25), and celastrol (26), have been observed to”
BackgroundDing, W., Yan, Z., Zak, R., Saavedra, M., Rodman, D. M., & Engelhardt, J. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7361-7366.2003 · Cited by 73
Chuah, M., Collen, D., & VandenDriessche, T. (2001) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200101/02)3:1<3::aid-jgm167>3.0.co;2-h · Cited by 70
Production and Characterization of PANI/TiO2 Nanocomposites: Anticorrosive Application on 316LN SS
Rathod, R. C., Umare, S. S., Didolkar, V. K., Shambharkar, B. H., & Patil, A. P. (2013) · Transactions of the Indian Institute of Metals · doi:10.1007/s12666-012-0231-9 · Cited by 68
Hacker, U. T., Wingenfeld, L., Kofler, D. M., Schuhmann, N. K., Lutz, S., Herold, T., King, S. B. S., Gerner, F. M., Perabo, L., Rabinowitz, J., et al. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.782 · Cited by 63
Self-citationGoodrich, L. R., Phillips, J. N., McIlwraith, C. W., Foti, S. B., Grieger, J. C., Gray, S. J., & Samulski, R. J. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.61 · Cited by 63
Self-citationProteasome Inhibitors: Complex Tools for a Complex Enzyme
Bogyo, M. S., & Wang, E. W. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59414-4_8 · Cited by 62 · cited 1×
“and serine (MG-132 and bortezomib) proteases (29).”
Denby, L., Nicklin, S. A., & Baker, A. H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302564 · Cited by 61 · cited 1×
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
ResultJennings, K., Miyamae, T., Traister, R., Marinov, A., Katakura, S., Sowders, D., Trapnell, B., Wilson, J. M., Gao, G., & Hirsch, R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.020 · Cited by 59 · cited 1×
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
ResultCheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G. V., Park, M., Stacpoole, P. W., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 59
Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells
Liu, Y., Joo, K.-I., & Wang, P. (2012) · Gene Therapy · doi:10.1038/gt.2012.41 · Cited by 59
Binny, C., McIntosh, J., Della Peruta, M., Kymalainen, H., Tuddenham, E. G. D., Buckley, S. M. K., Waddington, S. N., McVey, J. H., Spence, Y., Morton, C. L., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377630 · Cited by 54
Interaction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1
Anwar, A., Siegel, D. M., Kepa, J. K., & Ross, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111576200 · Cited by 51 · cited 1×
“We treated HeLa cells twice with phenylmethanesulfonyl fluoride (PMSF) to inhibit serine proteases as has been described (39), coadministered 1,000 vg/cell rAAV2 with the second dose, and analyzed transduction by luciferase assay at 24 h.”
MethodJohnson, J. S., Gentzsch, M., Zhang, L., Ribeiro, C. M. P., Kantor, B., Kafri, T., Pickles, R. J., & Samulski, R. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002053 · Cited by 48 · cited 1×
“Consequently, two hypotheses can be drawn for how proteasome inhibition enhances rAAV transduction: (i) proteasome inhibition prevents the degradation of rAAV capsids, increasing the rAAV pool available to complete transduction; (ii) as misfolded protein responses can enhance rAAV transduction (41), a general misfolde…”
BackgroundSelf-citationMitchell, A. M., Li, C., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.03443-12 · Cited by 41 · cited 5×
“Ex vivo quantification of transduction by luciferase assay and vector genome copy number (10) confirmed the live imaging data (Fig.”
BackgroundMethodSelf-citationLiver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
Prasad, K.-M. R., Xu, Y., Yang, Z., Toufektsian, M.-C., Berr, S. S., & French, B. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300071 · Cited by 33
Celastrol enhances AAV1-mediated gene expression in mice adipose tissues
Zhang, F., Jia, S.-Q., Zheng, S.-P., & Ding, W. (2010) · Gene Therapy · doi:10.1038/gt.2010.120 · Cited by 31 · cited 2×
“bortezomib (11, 25), and celastrol (26), have been observed to”
BackgroundResultQiu, M., Chen, Y., Cheng, L., Chu, Y., Song, H., & Wu, Z. (2013) · Journal of Virology · doi:10.1128/jvi.00869-13 · Cited by 27 · cited 1×
“Furthermore, the strategies employed to address these questions could now be applied to other viruses which are thought to be affected by proteasomal activity, such as hepatitis B virus or herpes simplex virus (42, 43).”
MethodJu, X., Lou, S., Wang, W., Peng, J.-Q., & Tian, H. (2004) · PubMed · Cited by 27
Perspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 25 · cited 1×
“enhancing rAAV-mediated liver transduction, our data suggest that other second-generation PIs in development, such as ONX0912, MLN9708, and marizomib (44), should be examined for enhancement of rAAV transduction in vivo.”
BackgroundAAV-6 mediated efficient transduction of mouse lower airways
Li, W., Zhang, L., Wu, Z., Pickles, R. J., & Samulski, R. J. (2011) · Virology · doi:10.1016/j.virol.2011.06.009 · Cited by 22
Self-citationInhibition of hepatitis B virus production in vitro by proteasome inhibitor MG132.
Wang, Y., Li, X., Yu, Y., Tang, Z., & Zang, G. (2013) · PubMed · doi:10.5754/hge11250 · Cited by 3 · cited 1×
“Furthermore, the strategies employed to address these questions could now be applied to other viruses which are thought to be affected by proteasomal activity, such as hepatitis B virus or herpes simplex virus (42, 43).”
Method
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationBeck, H., Härter, M., Haß, B., Schmeck, C., & Baerfacker, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.015 · Cited by 198
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Metadata
- Authors
- Mitchell, A. M., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2013-12
- Volume
- 87
- Issue
- 23
- Pages
- 13035-13041
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3838122
- OpenAlex
- W2097180939
- Cited by
- 63
- References
- 47
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 8 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 3
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5u54ar056953-05, 5U54AR056953)
- University of North Carolina at Chapel Hill
- National Institute of Allergy and Infectious Diseases (R01AI072176, R01AI080726, T32AI007419)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084033)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U54AR056953, U54-AR056953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV transduction, proteasome inhibitors, carfilzomib, bortezomib, MG132, serine protease inhibition, cysteine protease inhibition, recombinant adeno-associated virus, gene delivery
- MeSH terms
- Dependovirus, Cell Line, Chymotrypsin, Humans, Oligopeptides, Parvoviridae Infections, Transduction, Genetic, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.